DK1005358T3 - Anvendelse af et neurturinprotein-produkt til forebyggelse og behandling af hørenedsættelse - Google Patents

Anvendelse af et neurturinprotein-produkt til forebyggelse og behandling af hørenedsættelse

Info

Publication number
DK1005358T3
DK1005358T3 DK98937956T DK98937956T DK1005358T3 DK 1005358 T3 DK1005358 T3 DK 1005358T3 DK 98937956 T DK98937956 T DK 98937956T DK 98937956 T DK98937956 T DK 98937956T DK 1005358 T3 DK1005358 T3 DK 1005358T3
Authority
DK
Denmark
Prior art keywords
protein product
hearing loss
prevention
treatment
neurturin protein
Prior art date
Application number
DK98937956T
Other languages
English (en)
Inventor
Ella Magal
John M Delaney
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1005358T3 publication Critical patent/DK1005358T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dairy Products (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK98937956T 1997-07-30 1998-07-17 Anvendelse af et neurturinprotein-produkt til forebyggelse og behandling af hørenedsættelse DK1005358T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5418497P 1997-07-30 1997-07-30
US09/106,486 US6043221A (en) 1997-07-30 1998-06-29 Method for preventing and treating hearing loss using a neuturin protein product
PCT/US1998/014600 WO1999006064A1 (en) 1997-07-30 1998-07-17 Method for preventing and treating hearing loss using a neurturin protein product

Publications (1)

Publication Number Publication Date
DK1005358T3 true DK1005358T3 (da) 2003-02-24

Family

ID=26732740

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98937956T DK1005358T3 (da) 1997-07-30 1998-07-17 Anvendelse af et neurturinprotein-produkt til forebyggelse og behandling af hørenedsættelse

Country Status (10)

Country Link
US (2) US6043221A (da)
EP (1) EP1005358B1 (da)
JP (1) JP2001525316A (da)
AT (1) ATE230607T1 (da)
AU (1) AU8658298A (da)
CA (1) CA2298414C (da)
DE (1) DE69810635T2 (da)
DK (1) DK1005358T3 (da)
ES (1) ES2190093T3 (da)
WO (1) WO1999006064A1 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
DE19807426A1 (de) * 1998-02-23 1999-10-14 Otogene Biotechnologische Fors Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs
US6423321B2 (en) 1999-02-24 2002-07-23 Edward L. Tobinick Cytokine antagonists for the treatment of sensorineural hearing loss
JP2003530817A (ja) 1999-06-01 2003-10-21 ベイラー カレッジ オブ メディスン 聴覚障害、変形性関節症および細胞の異常増殖に関するａｔｏｎａｌ関連配列の治療用途のための組成物および方法
US7053200B1 (en) 1999-06-01 2006-05-30 Baylor College Of Medicine Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
DE10025152A1 (de) * 2000-05-23 2001-12-06 Marlies Knipper Neurotrophin stimulierende Substanzen, insbesondere Thyroidhormon (T3) oder Schilddrüsenhormon stimulierende Substanzen, für die therapeutische Behandlung von lärm-und altersbedingter Schwerhörigkeit
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
AUPR879201A0 (en) * 2001-11-09 2001-12-06 Cochlear Limited Subthreshold stimulation of a cochlea
US20100030301A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Electrical stimulation for modulation of neural plasticity
US20100030130A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Pharmaceutical intervention for modulation of neural plasticity
US20050171579A1 (en) * 2001-11-09 2005-08-04 Claudia Tasche Stimulating device
AU2003208900A1 (en) * 2002-01-30 2003-09-02 House Ear Institute L-carnitine for treatment of hearing loss
EP2275118A3 (en) 2002-05-29 2011-10-19 DeveloGen Aktiengesellschaft Pancreas-specific proteins
CN100335502C (zh) * 2002-06-27 2007-09-05 学校法人日本医科大学 外淋巴瘘的检测方法
AU2003259846A1 (en) * 2002-08-16 2004-03-03 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
DE60332748D1 (de) 2002-10-02 2010-07-08 Anges Mg Inc Arzneimittel gegen hörfunktionsstörungen
WO2004066975A1 (en) 2002-12-18 2004-08-12 Hough Ear Institute Otologic nanotechnology
US8651113B2 (en) * 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7723311B2 (en) * 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
DE602004021847D1 (de) 2003-11-27 2009-08-13 Develogen Ag Verfahren zur prävention und behandlung von diabetes mit neurturin
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
KR20070027621A (ko) * 2004-06-08 2007-03-09 알자 코포레이션 4-성분 축합 반응에 의한 고분자 콘쥬게이트의 제조
CA2569724A1 (en) 2004-06-15 2005-12-29 Cochlear Americas Automatic determination of the threshold of an evoked neural response
WO2006099325A2 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of treating ear infections
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
US9265933B2 (en) 2005-09-08 2016-02-23 Massachusetts Eye And Ear Infirmary Cochlear implants containing biological cells and uses thereof
EP1872790A1 (en) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
WO2009059755A2 (en) * 2007-11-05 2009-05-14 Develogen Aktiengesellschaft Novel neurturin conjugates for pharmaceutical use
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
EP2278999B1 (en) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
CN102695723A (zh) * 2009-10-30 2012-09-26 中枢神经系统治疗学公司 改进的神经营养因子分子
US20110195488A1 (en) * 2010-02-10 2011-08-11 Selinfreund Richard H Devices for collection and stabilization of biomarkers in liquid samples
ES2906726T3 (es) * 2014-06-12 2022-04-20 Adare Pharmaceuticals Usa Inc Composiciones de administración de fármaco de liberación prolongada
FR3024361B1 (fr) * 2014-07-30 2017-11-24 Affichem Utilisation de derives de sterols pour traitement de la perte auditive neurosensorielle et composition correspondante
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
WO2020045980A1 (en) * 2018-08-28 2020-03-05 Industry-Academic Cooperation Foundation, Yonsei University Pharmaceutical composition for treating or preventing sensorineural hearing loss
CN110124014A (zh) * 2019-05-16 2019-08-16 杭州师范大学 重组人神经突起生长因子Neuritin蛋白的应用及一种用于治疗听神经病的药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5106627A (en) * 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
WO1990006952A1 (fr) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
WO1991010470A1 (en) * 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
AU679167B2 (en) * 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
SG48813A1 (en) * 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5658785A (en) * 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
AU1121997A (en) * 1995-11-29 1997-06-19 Amgen, Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product

Also Published As

Publication number Publication date
ES2190093T3 (es) 2003-07-16
DE69810635D1 (de) 2003-02-13
AU8658298A (en) 1999-02-22
WO1999006064A1 (en) 1999-02-11
CA2298414A1 (en) 1999-02-11
CA2298414C (en) 2004-09-28
US6043221A (en) 2000-03-28
DE69810635T2 (de) 2003-05-28
EP1005358A1 (en) 2000-06-07
US6274554B1 (en) 2001-08-14
JP2001525316A (ja) 2001-12-11
ATE230607T1 (de) 2003-01-15
EP1005358B1 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
DK1005358T3 (da) Anvendelse af et neurturinprotein-produkt til forebyggelse og behandling af hørenedsættelse
DK0822829T3 (da) Anvendelse af glial neurotrofisk faktor (GDNF) til behandling af høreforstyrrelser
EP1449834A3 (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
ATE233738T1 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
EP0335901A4 (en) Methods and compositions for the treatment of non-ige-mediated diseases
ITTO930721A0 (it) Elettrodo impiantabile, ad esempio per pacemaker, defibrillatori e similari.
DE69408309D1 (de) Mittel zum künstlichen sonnenbräunen und zum schutz der haut gegen uv-strahlen
DE69305776D1 (de) Behandlung neurodegenerativer Krankheiten
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
ATE319712T1 (de) Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
IE791235L (en) Acyl-derivatives of carnitine.
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
GB9425730D0 (en) Compounds
EP0821969A3 (en) Medicinal Composition comprising TCF-II
EP1304119A3 (en) Method for preventing and treating hearing loss using a neurturin protein product
TR199800850T2 (xx) Kan� d�zenleyici bile�imler.
TR200000916T2 (tr) İkameli piperidin türevleri.
UA29648A (uk) Спосіб лікування хімічних опіків стравоходу
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії